CHU Bordeauxt
- Address
- lock Available on a paid plan
Digestive System Diseases
The digestive system diseases research at CHU Bordeauxt concentrates on liver cancer, evaluating novel combination therapies to improve outcomes for patients with unresectable disease.
- Unresectable hepatocellular carcinoma
- Autophagy inhibitor combined with atezolizumab‑bevacizumab
- First‑line treatment strategies
- Safety and tolerability assessments
With 10 active trials and a multidisciplinary team of 21 investigators, the site advances therapeutic options for liver malignancies.
Immune System Diseases
The immune system diseases program explores targeted agents for autoimmune skin conditions and systemic lupus, aiming to reduce disease activity and improve quality of life.
- Active discoid and subacute cutaneous lupus erythematosus
- Moderate to severe hidradenitis suppurativa
- Non‑segmental vitiligo
- Immunotherapy‑naïve cutaneous squamous cell carcinoma
These studies integrate innovative JAK inhibitors and biologics, reflecting the site’s commitment to personalized immunomodulation.
Musculoskeletal Diseases
In the realm of musculoskeletal diseases, CHU Bordeauxt is evaluating new regimens for bone‑derived sarcomas, seeking optimal dosing alongside standard chemotherapy.
- Metastatic Ewing sarcoma
- Regorafenib combined with VDC/IE chemotherapy
- Phase 2 dose‑finding studies
- Safety monitoring and early efficacy signals
The collaboration between oncology and orthopedic specialists supports rapid translation of findings into clinical practice.
Neoplasms
The neoplasms portfolio spans solid tumors and melanoma, testing cutting‑edge immunotherapies and targeted agents to extend survival in high‑risk patients.
- Resected stage III/IV melanoma adjuvant therapy
- Advanced cutaneous squamous cell carcinoma
- Metastatic solid tumors across multiple histologies
- Pharmacokinetic similarity study with nivolumab
Across multiple trials, the site leverages its robust oncology infrastructure to accelerate drug development.
Skin and Connective Tissue Diseases
Focused on skin and connective tissue diseases, the center conducts trials on disorders such as lupus, vitiligo, and hidradenitis, evaluating both efficacy and safety of novel molecules.
- Deucravacitinib in active DLE/SCLE
- MK‑6194 for non‑segmental vitiligo
- Upadacitinib in adults and adolescents with hidradenitis suppurativa
- INCB099280 in advanced cutaneous squamous cell carcinoma
By integrating dermatology and immunology expertise, CHU Bordeauxt aims to deliver better therapeutic options for patients with chronic skin disease.
Virus Diseases
The virus diseases research agenda includes a randomized strategy to optimise antiviral regimens for immunocompromised patients with Covid‑19.
- OPTICOV study of nirmatrelvir/ritonavir plus remdesivir
- Extended treatment duration assessment (5 vs 10 days)
- Viral load reduction measured by RT‑PCR Ct values
- Safety monitoring in vulnerable populations
These investigations support evidence‑based management of emerging infectious threats and align with the hospital’s public health mission.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 67 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 64 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
lock +9 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC8trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHU Bordeauxt
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma | Incyte Corp. | Phase II | Not Yet Recruiting | Oct 2023 | Mar 2026 |
IMP list
lock Showing 1 of 67 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 10 | Unknown | 2019-03-04 | 2022-03-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.